Plus Therapeutics Inc
PSTV0.739USD
+0.154+26.34%
종가 08/04, 16:00（ET）시세는 15분 지연됩니다
12.56M시가총액
손실P/E TTM
자세한 내용은 Plus Therapeutics Inc 회사
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers. The Company combines image-guided local beta radiation and targeted drug delivery approaches. The Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). Its radiotherapeutic candidate, rhenium (186Re) obisbemeda, is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC). The Company’s Rhenium (186Re) obisbemeda, a novel injectable radiotherapy designed to deliver targeted, high dose radiation directly into GBM tumors. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers.
회사 정보
종목 코드 PSTV
회사 이름Plus Therapeutics Inc
상장일Aug 09, 2000
CEODr. Marc H. Hedrick, M.D.
직원 수21
유형Ordinary Share
회계 연도 종료Aug 09
주소4200 Marathon Blvd.
도시AUSTIN
증권 거래소NASDAQ Capital Market Consolidated
국가United States of America
우편 번호78756
전화17372557194
웹사이트http://www.plustherapeutics.com/
종목 코드 PSTV
상장일Aug 09, 2000
CEODr. Marc H. Hedrick, M.D.
회사 임원
이름
이름/직위
직위
주식 보유
변동
Dr. Robert P. Lenk, Ph.D.
Dr. Robert P. Lenk, Ph.D.
Independent Director
Independent Director
29.33K
--
Mr. Howard Clowes, J.D.
Mr. Howard Clowes, J.D.
Independent Director
Independent Director
26.50K
--
Dr. Marc H. Hedrick, M.D.
Dr. Marc H. Hedrick, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
20.43K
--
Mr. Kyle Guse, Esq.
Mr. Kyle Guse, Esq.
Independent Director
Independent Director
--
--
Dr. Annigje (An) van Es-Johansson, M.D.
Dr. Annigje (An) van Es-Johansson, M.D.
Independent Director
Independent Director
--
--
Mr. Andrew Sims, CPA
Mr. Andrew Sims, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Michael Stanley Rosol, Ph.D.
Dr. Michael Stanley Rosol, Ph.D.
Chief Development Officer
Chief Development Officer
--
--
Mr. Richard J. (Rick) Hawkins
Mr. Richard J. (Rick) Hawkins
Independent Chairman of the Board
Independent Chairman of the Board
--
--
이름
이름/직위
직위
주식 보유
변동
Dr. Robert P. Lenk, Ph.D.
Dr. Robert P. Lenk, Ph.D.
Independent Director
Independent Director
29.33K
--
Mr. Howard Clowes, J.D.
Mr. Howard Clowes, J.D.
Independent Director
Independent Director
26.50K
--
Dr. Marc H. Hedrick, M.D.
Dr. Marc H. Hedrick, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
20.43K
--
Mr. Kyle Guse, Esq.
Mr. Kyle Guse, Esq.
Independent Director
Independent Director
--
--
Dr. Annigje (An) van Es-Johansson, M.D.
Dr. Annigje (An) van Es-Johansson, M.D.
Independent Director
Independent Director
--
--
Mr. Andrew Sims, CPA
Mr. Andrew Sims, CPA
Chief Financial Officer
Chief Financial Officer
--
--
수익 분석
통화: USD마지막 업데이트: Tue, Mar 4
통화: USD마지막 업데이트: Tue, Mar 4
FY2018
사업별USD
이름
수익
비율
Consumable
2.17M
81.21%
Other products
277.00K
10.37%
Device
225.00K
8.42%
지역별USD
이름
수익
비율
Japan
2.06M
77.05%
Americas
293.00K
10.97%
EMEA
270.00K
10.11%
Asia Pacific
50.00K
1.87%
사업별
지역별
사업별USD
이름
수익
비율
Consumable
2.17M
81.21%
Other products
277.00K
10.37%
Device
225.00K
8.42%
주식 보유 통계
마지막 업데이트: Fri, Jun 27
마지막 업데이트: Fri, Jun 27
주주
주주 유형
주주
주주
비율
Great Point Capital LLC
1.46%
S.H.N. Financial Investments Ltd
1.46%
HRT Financial LP
0.17%
Susquehanna International Group, LLP
0.13%
Geode Capital Management, L.L.C.
0.09%
Other
96.68%
주주
주주
비율
Great Point Capital LLC
1.46%
S.H.N. Financial Investments Ltd
1.46%
HRT Financial LP
0.17%
Susquehanna International Group, LLP
0.13%
Geode Capital Management, L.L.C.
0.09%
Other
96.68%
주주 유형
주주
비율
Investment Advisor
1.91%
Corporation
1.46%
Individual Investor
0.24%
Investment Advisor/Hedge Fund
0.10%
Research Firm
0.07%
Hedge Fund
0.04%
Other
96.19%
기관 주식 보유
마지막 업데이트: Tue, Jul 1
마지막 업데이트: Tue, Jul 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q2
34
2.31M
3.81%
-2.38M
2025Q1
40
2.31M
11.85%
+1.40M
2024Q4
42
829.50K
14.07%
-98.90K
2024Q3
44
822.91K
13.96%
-122.82K
2024Q2
46
793.04K
13.90%
-131.21K
2024Q1
46
164.14K
3.77%
-119.25K
2023Q4
47
203.09K
4.50%
+1.47K
2023Q3
47
127.65K
2.90%
-110.39K
2023Q2
45
114.35K
4.03%
-124.09K
2023Q1
46
144.27K
6.00%
-86.09K
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Great Point Capital LLC
885.45K
1.74%
--
--
Apr 18, 2025
S.H.N. Financial Investments Ltd
885.45K
1.74%
--
--
Apr 18, 2025
HRT Financial LP
102.06K
0.2%
+102.06K
--
Mar 31, 2025
Susquehanna International Group, LLP
80.50K
0.16%
+80.50K
--
Mar 31, 2025
Geode Capital Management, L.L.C.
57.05K
0.11%
-1.10K
-1.89%
Mar 31, 2025
Petersen (Gregory B)
48.92K
0.1%
--
--
Mar 04, 2025
Virtu Americas LLC
40.03K
0.08%
+40.03K
--
Mar 31, 2025
UBS Financial Services, Inc.
33.44K
0.07%
+33.44K
--
Mar 31, 2025
The Vanguard Group, Inc.
32.54K
0.06%
--
--
Mar 31, 2025
Lenk (Robert P)
29.33K
0.06%
--
--
Apr 18, 2025
더 보기
관련 ETF
이름
비율
데이터 없음
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
Apr 28, 2023
Merger
15<1
Apr 28, 2023
Merger
15<1
Apr 28, 2023
Merger
15<1
Apr 28, 2023
Merger
15<1
날짜
유형
비율
Apr 28, 2023
Merger
15<1
Apr 28, 2023
Merger
15<1
Apr 28, 2023
Merger
15<1
Apr 28, 2023
Merger
15<1
